Canellas João Vitor Dos Santos, Ritto Fabio Gamboa, Tiwana Paul
Department of Research, INPLASY, Inc. - International Platform of Registered Systematic Review and Meta-analysis Protocols, Delaware, United States.
Department of Oral and Maxillofacial Surgery, College of Dentistry, The University of Oklahoma, United States.
Br J Oral Maxillofac Surg. 2022 Oct;60(8):1035-1043. doi: 10.1016/j.bjoms.2022.05.003. Epub 2022 May 25.
A variety of corticosteroids are available as an alternative to reduce inflammatory complications after mandibular third molar surgery (3MS). However, it is unclear which are the best preoperative drugs, doses, and routes of administration. A frequentist network meta-analysis was performed to assess the comparative effectiveness of corticosteroids to reduce inflammatory complications after 3MS. We searched Embase, PubMed, and the Cochrane Library without language restrictions. Only randomised clinical trials (RCTs) were included. We obtained the relative effectiveness using network meta-analysis and an estimate of the relative ranking of interventions according to their effects. Our search yielded 2427 results, from which 61 studies involving 3561 subjects fulfilled our inclusion criteria. Five corticosteroids (dexamethasone, betamethasone, methylprednisolone, prednisolone, and triamcinolone) were compared. Dexamethasone 8mg via submucosal injection (-3.58[-6.98; -0.17]) and via pterygomandibular injection (-3.56[-6.30; -0.82]) were significantly more effective than placebo to reduce oedema after 3MS. The ranking analysis showed that dexamethasone 8mg via submucosal injection and via oral tablets were the interventions with the highest probability of being the most effective methods to reduce oedema after 3MS (p values = 0.71 and 0.75, respectively). Compared with placebo, only dexamethasone 8mg via submucosal injection effectively reduced pain in the first and second days after 3MS (-30.95[-43.41; -18.49]) and (-15.25[-23.27; -7.22]), respectively. Overall, corticosteroids reduced inflammatory complications after 3MS and did not show any serious adverse effects. Among the corticosteroids reviewed, dexamethasone 8mg was the best preoperative option to control inflammatory complications after 3MS. Further RCTs are needed to confirm the optimal route of administration.
有多种皮质类固醇可作为减少下颌第三磨牙手术(3MS)后炎症并发症的替代药物。然而,目前尚不清楚哪种是最佳的术前用药、剂量和给药途径。进行了一项频率学派网状Meta分析,以评估皮质类固醇减少3MS后炎症并发症的相对疗效。我们在没有语言限制的情况下检索了Embase、PubMed和Cochrane图书馆。仅纳入随机临床试验(RCT)。我们使用网状Meta分析获得了相对疗效,并根据干预措施的效果对其相对排名进行了估计。我们的检索产生了2427条结果,其中61项涉及3561名受试者的研究符合我们的纳入标准。比较了五种皮质类固醇(地塞米松、倍他米松、甲泼尼龙、泼尼松龙和曲安奈德)。3MS后,8mg地塞米松经黏膜下注射(-3.58[-6.98;-0.17])和经翼下颌注射(-3.56[-6.30;-0.82])在减轻水肿方面显著优于安慰剂。排名分析表明,3MS后,8mg地塞米松经黏膜下注射和口服片剂是最有可能成为减轻水肿最有效方法的干预措施(p值分别为0.71和0.75)。与安慰剂相比,仅8mg地塞米松经黏膜下注射能有效减轻3MS后第一天和第二天的疼痛(分别为-30.95[-43.41;-18.49])和(-15.25[-23.27;-7.22])。总体而言,皮质类固醇减少了3MS后的炎症并发症,且未显示任何严重不良反应。在所审查的皮质类固醇中,8mg地塞米松是控制3MS后炎症并发症的最佳术前选择。需要进一步的随机对照试验来确认最佳给药途径。